Adverse effects
are common.
“No serious adverse events” does not mean no side effects.
In the 2026 randomised trial of a manufactured formulation, adverse events were reported in 29 of 40 participants who received the active treatment. Nausea was common. None were classified as severe or serious during the controlled period, but that period was short.
An earlier phase 1 study of an intranasal formulation reported nasal discomfort, nausea, headache and vomiting. Its participants were selected healthy adults, screened to exclude seizure history, serious psychiatric concerns, pregnancy and MAOI use.
Those exclusions describe who was studied. They are not a clearance list, and a small screened sample cannot rule out rare harms. Bodily discomfort and psychological distress are also not evidence of progress, and should not be reinterpreted as such.